Application processes at NIH are changing. Applicant organizations are encouraged to start preparing for this transtion by registering with Grants.gov and NIH eRA Commons now. |
Shared Neurobiology of Fragile X Syndrome and Autism (R01)
Release Date: January 9, 2007
Announcement Number: PA-07-284
Application Receipt Date:
February 5, 2007
June 5, 2007
October 5, 2007
February 5, 2008
June 5, 2008
October 5, 2008
Funding Contact: Laura Mamounas, Ph.D.
Program Area: Neurogenetics
Also See:
http://grants.nih.gov/grants/guide/notice-files/NOT-MH-08-023.html
Brief Description:
The National Institute of Mental Health (NIMH), National Institute of Neurological Disorders and Stroke (NINDS) and the National
Institute of Child Health and Human Development (NICHD) have entered into a public-private partnership with the Canadian Institutes
of Health Research (CIHR), the Health Research Board, Ireland (HRB), Cure Autism Now (CAN), the National Alliance for Autism
Research (NAAR), Autism Speaks and the FRAXA Research Foundation (FRAXA) to jointly sponsor this Funding Opportunity Announcement
(FOA), which is aimed at characterizing, understanding and treating etiological and pathophysiological mechanisms common to
both Fragile X syndrome (FXS) and autism (including autism spectrum disorders such as Rett syndrome). Between 2.5% and 6%
of individuals with autistic feature have FXS, and approximately 15% to 25% of children with FXS have autism. An additional
50% to 90% of children with FXS exhibit some symptoms and features associated with autism, including poor eye contact, hand
flapping, hand biting, speech perseveration and other language abnormalities and problems, as well as tactile defensiveness,
mental retardation in the moderate to severe range, developmental delay, sensory hyperarousal, and social anxiety with mood
liability. Researchers have argued that autism and autistic symptoms in FXS reflect a common etiological or pathophysiological
pathway underlying the two conditions. Ongoing basic neuroscience research on FXS in model systems like the mouse and fly
are providing a wealth of information at multiple levels – subcellular, cellular, and intercellular networks or circuits –
to delineate the neurobiology of this disorder. These studies should dissect components of the neurobiology of autism, especially
in patients with both FXS and autism, and identify novel targets for new drugs to treat both disorders. Applications submitted
in response to this FOA should focus on a topic related to understanding neural pathways, circuits, systems and molecules
that play a role in the etiology or pathophysiology of FXS and may be implicated in autism (including autism spectrum disorders
such as Rett syndrome). Studies emphasizing the identification of drug targets for new therapeutic drugs to treat FXS and
autism are particularly encouraged. Research projects supported under this FOA that include human subjects should include
children affected with both FXS and autism and animal studies may include several models systems, e.g., mouse, fly and zebrafish.
Basic neuroscience research in model systems should focus on both FXS and autism.
Choose an option to view additional funding announcements |
New Announcements | Research Area | RFAs Only | PAs Only | RFPs Only | Notices Only | Supplements Only | All Announcements | Archives |